WASHINGTON — June 27, 2019 — Arlington Capital Partners, a Washington-based private equity firm, announced today it has completed a majority growth investment in Riverpoint Medical. The investment in Riverpoint marks the first deal out of Arlington’s $1.7 billion Fund V, which closed earlier this week. Headquartered in Portland, Oregon, Riverpoint Medical is a leading developer, designer, and manufacturer of medical devices focused on advanced bio-medical textile technologies. The Company has a strong history of industry leading product innovation and intellectual property development across bioabsorbable sutures, high strength medical fiber and suture-based implantable devices. Riverpoint’s advanced polymer technologies address the stringent demands of large and rapidly growing global markets including wound closure, sports medicine, animal health and regenerative medicine.
Matt Altman, a managing partner at Arlington, said, “Arlington is thrilled to partner with the Riverpoint team to continue building a leading manufacturer of advanced textile-based medical devices. Riverpoint’s ability to develop innovative technologies coupled with its unique manufacturing processes provide a strong platform to accelerate growth in large addressable markets. Our investment in Riverpoint continues Arlington’s history of building differentiated, high-growth medical device manufacturers in partnership with company founders and existing senior management.”
Pat Ferguson, CEO of Riverpoint, stated, “We chose to partner with Arlington because of its long track record of success investing in, and scaling, medical device manufacturers. We are extremely pleased to work together with Arlington to take Riverpoint to the next level of growth as Arlington shares our vision for expanding Riverpoint’s capabilities to better serve our customers and employees. Arlington’s ability to provide significant strategic and capital support is differentiated and will further enable Riverpoint to expand our offerings to our clients, increase our manufacturing capacity, and most importantly, help enhance surgical outcomes.”
Gordon Auduong, a vice president of Arlington, added: “We have been very impressed with the company’s ability to capitalize on the growth trends in the sports medicine and animal health markets. We believe that Arlington can provide the strategic support and investments necessary to accelerate this exciting platform. We look forward to partnering with the highly talented Riverpoint management team to propel the company through its next phase of growth.”
Riverpoint’s founders and senior management have all made substantial investments as part of the transaction and will continue to lead the company’s strategic growth initiatives in the future. The Walden Group served as advisor to the company on the transaction.
Posted June 27, 2019
Source: Arlington Capital Partners
